title: Effect of early vs. late administration of 4-hydroxyphenylretinamide (4-HPR) on N-methyl-N-nitrosourea (MNU)-induced mammary tumorigenesis.
abstract: Mammary tumors were induced in 48-52-day-old female Sprague-Dawley rats in metestrus or diestrus with a single jugular injection of MNU (50 mg/kg). Control rats received the saline vehicle (Group 4 n = 9). Rats were fed 4% Teklad diet containing either 0 (Group 3, n = 20) or 782 mg 4-HPR/kg diet. 4-HPR supplementation was initiated either 1 week prior to (Group 1, n = 14) or 4 weeks following MNU administration (Group 2, n = 19). Neither body weight nor food intake differed significantly between treatment groups. Feeding of 4-HPR 1 week prior to tumor induction reduced the number of tumors (0.8 +/- .2) when compared to MNU control rats (2.1 +/- .4). Immunohistochemical staining of mammary tumor sections for PCNA was quantitated by microdensitometry and expressed as an HSCORE. No differences in HSCORE were observed between tumor groups although the percentage of nuclear area occupied by intermediate and darkly stained nuclei was reduced in the late 4-HPR group. GC-->AT transitions in codon 12 of the H-ras gene were detected in 50% (12/24) of MNU control tumors, 60% (6/10) of early 4-HPR tumors, and 38% (6/16) of late 4-HPR tumors. Mutation rates did not differ significantly between groups. 4-HPR appears to be a more effective chemopreventive when fed during the initiation period.
authors.affiliation: Department of Surgery, Medical College of Ohio, Toledo 43699, USA.
authors.forename: K A
authors.initials: KA
authors.lastname: Crist
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.forename: R A
authors.initials: RA
authors.lastname: Lubet
authors.forename: V E
authors.initials: VE
authors.lastname: Steele
authors.forename: G J
authors.initials: GJ
authors.lastname: Kelloff
authors.forename: M
authors.initials: M
authors.lastname: You
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001483:Base Sequence; D002273:Carcinogens / Q000633:toxicity*; D003062:Codon; D017931:DNA Primers; D004334:Drug Administration Schedule; D005247:Feeding Behavior / Q000187:drug effects; D005260:Female; D017313:Fenretinide / Q000008:administration & dosage* / Q000494:pharmacology; D011905:Genes, ras; D007150:Immunohistochemistry; D008325:Mammary Neoplasms, Experimental / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D008770:Methylnitrosourea / Q000633:toxicity*; D009154:Mutation; D051381:Rats; D017207:Rats, Sprague-Dawley; D016196:S Phase; D015430:Weight Gain / Q000187:drug effects
chemical_list: D016588:Anticarcinogenic Agents; D002273:Carcinogens; D003062:Codon; D017931:DNA Primers; D017313:Fenretinide; D008770:Methylnitrosourea